Stammdaten
BridgeBio Pharma, Inc. beschäftigt sich mit der Entdeckung, Entwicklung und Bereitstellung verschiedener Medikamente für genetische Erkrankungen. Das Unternehmen hat eine Pipeline mit 30 Entwicklungsprogrammen, die Produktkandidaten von früher Entdeckung bis zu fortgeschrittener Entwicklung umfassen. Seine in Entwicklung befindlichen Produkte umfassen AG10 und BBP-265, ein Kleinmolekül-Stabilisator von Transthyretin oder TTR, das sich in Phase-3-Studien zur Behandlung von TTR-Amyloidose-Kardiomyopathie oder ATTR-CM befindet; BBP-831, ein Kleinmolekül selektiver FGFR1-3 Inhibitor, der sich in Phase-2-Studien zur Behandlung von Achondroplasie bei pädiatrischen Patienten befindet; und BBP-631, ein AAV5-Gen-Transfer-Produktkandidat, der sich in Phase-2-Studien zur Behandlung von kongenitaler Adrenalhyperplasie oder CAH, verursacht durch 21-Hydroxylase-Mangel oder 21OHD, befindet. Das Unternehmen entwickelt auch Encaleret, einen Kleinmolekül-Antagonisten des Calcium-Sensing-Rezeptors oder CaSR, das sich in Phase-2-Proof-of-Concept-Studien für Autosomal Dominante Hypocalcämie Typ 1 oder ADH1 befindet; und BBP-711 zur Behandlung von Hyperoxalurie sowie Patienten mit rezidivierenden Nierensteinen. Darüber hinaus beschäftigt es sich mit der Entwicklung von Produkten für Mendelsche, Onkologie- und Gentherapie-Erkrankungen. BridgeBio Pharma, Inc. hat Lizenz- und Kooperationsvereinbarungen mit der Leland Stanford Junior University; und den Regenten der University of California; Leidos Biomedical Research, Inc. Das Unternehmen wurde 2015 gegründet und hat seinen Hauptsitz in Palo Alto, Kalifornien.
Unternehmen & Branche
| Name | BridgeBio Pharma, Inc. |
|---|---|
| Ticker | BBIO |
| CIK | 0001743881 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 10806X102 |
|---|---|
| ISIN | US10806X1028 |
| Typ | Common Stock |
| Marktkapitalisierung | 16,73 Mrd. USD |
| Beta | 0,98 |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 3160 PORTER DR. SUITE 250, 94304 PALO ALTO, CA |
| Telefon | (650) 391-9740 |
| EIN (IRS) | 00-0000000 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | BridgeBio Pharma LLC (bis 2019) |
Bewertung
| KUV (P/S) | 33,32 vs. 35,25 (2021) ▼ |
|---|---|
| FCF-Rendite | -2,7 % vs. -20,8 % (2021) ▲ |
| Buyback-Rendite | 0,3 % vs. 8,1 % (2021) ▼ |
Qualität & Bilanz
| Bruttomarge | 95,8 % vs. 95,5 % (2021) ≈ |
|---|---|
| Operative Marge | -104,2 % vs. -827,1 % (2021) ▲ |
| Zinsdeckungsgrad | -9,9 vs. -12,3 (2021) ▲ |
| Forderungslaufzeit (DSO) | 101 T |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KUV (P/S) | 35,25 | 14,78 | 759,77 | 23,50 | 29,67 | 28,85 | |
| FCF-Rendite | -20,8 % | -37,0 % | -7,5 % | -10,0 % | -3,0 % | -2,7 % | |
| Buyback-Rendite | 8,1 % | 0,0 % | 0,0 % | 0,0 % | 0,3 % | 0,5 % | |
| Qualität & Bilanz | |||||||
| Bruttomarge | 95,5 % | 95,6 % | 73,7 % | 98,3 % | 95,8 % | 95,1 % | |
| Operative Marge | -827,1 % | -659,6 % | -6.528,8 % | -267,2 % | -104,2 % | -90,5 % | |
| Zinsdeckungsgrad | -12,3 | -6,4 | -7,5 | -6,5 | -9,9 | -11,0 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
BBIO
BridgeBio Pharma, Inc.
Effektiv
Sehr schwach
Handelsvolumen
Hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
47,6
85 neu, 180 erhöht, -223105K $ netto
Aktivist
36,7
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 70.18 | +19.8 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 69.48 | +21.0 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 76.68 | EMA50: 72.79 | |
| MACD-Histogramm | Bullisch | 10 % | 1.281 | Bullisch | |
| RSI(14) | Neutral | 10 % | 67.5 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 62.1 | Neutral | |
| ADX(14)+DI | Bullisch | 10 % | 34.6 | +DI: 37.7 / −DI: 11.7 | |
| Z-Score(60) | Bärisch | 5 % | 2.44 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 86.6 % | Hoch 90.17 / Tief 44.81 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 84.7 % | Upper 88.29 / Mid 74.53 / Lower 60.77 | |
| LinReg-Slope(60) | Neutral | 10 % | +0.1068 | R²=0.11 / annualisiert +38.0 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-09 | Cook Jennifer E. | Director | Open Market Sale | -36.167 | 84,00 | -3.038.028,00 | -360,1% | |
| 2026-07-09 | Cook Jennifer E. | Director | Open Market Sale | -112.422 | 90,00 | -10.117.980,00 | -1199,2% | |
| 2026-07-09 | Ellis Andrea | Director | Open Market Sale | -17.167 | 84,00 | -1.442.028,00 | -170,9% | |
| 2026-06-24 | Cook Jennifer E. | Director | Open Market Sale | -37.167 | 70,00 | -2.601.690,00 | -308,4% | |
| 2026-06-23 | Valantine Hannah | Director | Open Market Sale | -2.196 | 68,57 | -150.579,72 | -17,8% | |
| 2026-06-23 | Cook Jennifer E. | Director | Open Market Sale | -2.196 | 68,57 | -150.579,72 | -17,8% | |
| 2026-06-22 | Valantine Hannah | Director | Open Market Sale | -2.808 | 68,00 | -190.944,00 | -22,6% | |
| 2026-06-15 | Cook Jennifer E. | Director | Open Market Sale | -88.737 | 66,62 | -5.911.241,88 | -700,6% | |
| 2026-06-15 | Cook Jennifer E. | Director | Open Market Sale | -1.503 | 67,14 | -100.915,18 | -12,0% | |
| 2026-06-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -4.416 | 68,96 | -304.524,27 | -36,1% | |
| 2026-06-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -8.437 | 67,88 | -572.744,06 | -67,9% | |
| 2026-06-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.148 | 67,20 | -480.338,45 | -56,9% | |
| 2026-06-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.147 | 67,20 | -480.271,25 | -56,9% | |
| 2026-06-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -4.415 | 68,96 | -304.455,31 | -36,1% | |
| 2026-06-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -1.429 | 66,72 | -95.347,17 | -11,3% | |
| 2026-06-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -15.921 | 67,74 | -1.078.453,51 | -127,8% | |
| 2026-06-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -15.921 | 67,74 | -1.078.451,92 | -127,8% | |
| 2026-06-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -2.200 | 65,72 | -144.584,44 | -17,1% | |
| 2026-06-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -450 | 68,27 | -30.721,37 | -3,6% | |
| 2026-05-21 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -11.250 | 70,48 | -792.915,75 | -94,0% | |
| 2026-05-21 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -6.725 | 68,30 | -459.334,31 | -54,4% | |
| 2026-05-21 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.072 | 69,22 | -351.101,59 | -41,6% | |
| 2026-05-21 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -2.256 | 67,57 | -152.434,99 | -18,1% | |
| 2026-05-21 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -800 | 70,92 | -56.735,12 | -6,7% | |
| 2026-05-18 | Trimarchi Thomas | Officer, President and CFO | Open Market Sale | -10.456 | 64,82 | -677.706,69 | -80,3% | |
| 2026-05-18 | Trimarchi Thomas | Officer, President and CFO | Open Market Sale | -3.195 | 65,95 | -210.712,49 | -25,0% | |
| 2026-05-15 | Scott Randal W. | Director | Open Market Sale | -200 | 69,12 | -13.824,00 | -1,6% | |
| 2026-05-15 | Scott Randal W. | Director | Open Market Sale | -6.200 | 66,69 | -413.464,36 | -49,0% | |
| 2026-05-15 | Scott Randal W. | Director | Open Market Sale | -2.088 | 67,53 | -141.003,06 | -16,7% | |
| 2026-05-15 | Scott Randal W. | Director | Open Market Sale | -1.512 | 68,23 | -103.164,21 | -12,2% | |
| 2026-05-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.076 | 67,35 | -341.845,76 | -40,5% | |
| 2026-05-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -13.974 | 66,65 | -931.374,09 | -110,4% | |
| 2026-05-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -13.973 | 66,65 | -931.307,44 | -110,4% | |
| 2026-05-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.077 | 67,35 | -341.913,10 | -40,5% | |
| 2026-05-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -950 | 68,35 | -64.930,32 | -7,7% | |
| 2026-05-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -8.333 | 68,38 | -569.789,71 | -67,5% | |
| 2026-05-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -11.217 | 67,50 | -757.091,42 | -89,7% | |
| 2026-05-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -449 | 69,09 | -31.021,90 | -3,7% | |
| 2026-05-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -11.217 | 67,49 | -757.090,29 | -89,7% | |
| 2026-05-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -8.334 | 68,38 | -569.858,09 | -67,5% | |
| 2026-05-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -450 | 69,09 | -31.091,00 | -3,7% | |
| 2026-04-30 | Apuli Maricel | Officer, Chief Accounting Officer | Open Market Sale | -2.000 | 71,58 | -143.160,00 | -17,0% | |
| 2026-04-10 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -20.000 | 74,60 | -1.492.076,00 | -176,9% | |
| 2026-04-10 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -20.000 | 74,60 | -1.492.096,00 | -176,9% | |
| 2026-04-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.500 | 75,55 | -566.661,00 | -67,2% | |
| 2026-04-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.200 | 73,64 | -530.239,68 | -62,8% | |
| 2026-04-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.072 | 73,64 | -520.801,17 | -61,7% | |
| 2026-04-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.128 | 74,57 | -382.379,06 | -45,3% | |
| 2026-04-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.300 | 74,60 | -395.403,32 | -46,9% | |
| 2026-04-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.800 | 75,53 | -589.123,86 | -69,8% | |
| 2026-03-13 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -9.759 | 69,23 | -675.567,75 | -80,1% | |
| 2026-03-13 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -10.310 | 69,20 | -713.448,91 | -84,6% | |
| 2026-03-13 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -10.241 | 68,39 | -700.345,12 | -83,0% | |
| 2026-03-13 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -9.690 | 68,36 | -662.441,35 | -78,5% | |
| 2026-03-12 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.363 | 69,32 | -371.750,29 | -44,1% | |
| 2026-03-12 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -14.337 | 68,48 | -981.809,23 | -116,4% | |
| 2026-03-12 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -13.885 | 68,47 | -950.686,51 | -112,7% | |
| 2026-03-12 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.815 | 69,29 | -402.928,91 | -47,8% | |
| 2026-03-12 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -300 | 70,15 | -21.045,00 | -2,5% | |
| 2026-03-10 | Valantine Hannah | Director | Open Market Sale | -8.671 | 72,00 | -624.312,00 | -74,0% | |
| 2026-03-04 | Ellis Andrea | Director | Open Market Sale | -64.921 | 64,87 | -4.211.301,92 | -499,2% | |
| 2026-02-27 | Valantine Hannah | Director | Open Market Sale | -10.900 | 67,84 | -739.496,33 | -87,6% | |
| 2026-02-27 | Valantine Hannah | Director | Open Market Sale | -14.584 | 67,08 | -978.284,51 | -116,0% | |
| 2026-02-26 | Apuli Maricel | Officer, Chief Accounting Officer | Open Market Sale | -2.000 | 66,00 | -132.000,00 | -15,6% | |
| 2026-02-19 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -18.923 | 71,03 | -1.344.189,63 | -159,3% | |
| 2026-02-19 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -8.528 | 72,08 | -614.701,65 | -72,9% | |
| 2026-02-19 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -602 | 72,80 | -43.826,20 | -5,2% | |
| 2026-02-17 | Scott Randal W. | Director | Open Market Sale | -4.793 | 75,57 | -362.218,99 | -42,9% | |
| 2026-02-17 | Scott Randal W. | Director | Open Market Sale | -1.900 | 74,34 | -141.249,99 | -16,7% | |
| 2026-02-17 | Scott Randal W. | Director | Open Market Sale | -3.307 | 75,93 | -251.087,61 | -29,8% | |
| 2026-02-17 | Trimarchi Thomas | Officer, President and CFO | Open Market Sale | -13.400 | 74,71 | -1.001.071,12 | -118,7% | |
| 2026-02-17 | Trimarchi Thomas | Officer, President and CFO | Open Market Sale | -200 | 75,38 | -15.076,00 | -1,8% | |
| 2026-02-17 | Apuli Maricel | Officer, Chief Accounting Officer | Open Market Sale | -510 | 74,31 | -37.898,10 | -4,5% | |
| 2026-02-11 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -3.961 | 73,25 | -290.145,23 | -34,4% | |
| 2026-02-11 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.860 | 70,70 | -555.705,93 | -65,9% | |
| 2026-02-11 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.806 | 70,69 | -551.795,99 | -65,4% | |
| 2026-02-11 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -4.484 | 72,64 | -325.695,34 | -38,6% | |
| 2026-02-11 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -4.404 | 72,65 | -319.938,27 | -37,9% | |
| 2026-02-11 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -3.994 | 73,25 | -292.574,48 | -34,7% | |
| 2026-02-11 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -3.716 | 71,44 | -265.476,99 | -31,5% | |
| 2026-02-11 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -3.775 | 71,46 | -269.754,33 | -32,0% | |
| 2026-02-10 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -14.040 | 71,80 | -1.008.006,01 | -119,5% | |
| 2026-02-10 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.960 | 72,27 | -430.751,25 | -51,1% | |
| 2026-02-10 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.799 | 72,28 | -419.165,06 | -49,7% | |
| 2026-02-10 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -14.201 | 71,80 | -1.019.657,36 | -120,9% | |
| 2026-01-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -10.677 | 77,46 | -827.015,86 | -98,0% | |
| 2026-01-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -375 | 78,19 | -29.322,00 | -3,5% | |
| 2026-01-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -1.401 | 75,61 | -105.927,93 | -12,6% | |
| 2026-01-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -1.855 | 78,10 | -144.881,99 | -17,2% | |
| 2026-01-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -2.151 | 75,75 | -162.942,55 | -19,3% | |
| 2026-01-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -6.067 | 76,53 | -464.289,31 | -55,0% | |
| 2026-01-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -6.955 | 76,72 | -533.568,82 | -63,2% | |
| 2026-01-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -10.519 | 77,61 | -816.364,86 | -96,8% | |
| 2026-01-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -300 | 75,20 | -22.560,99 | -2,7% | |
| 2026-01-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -11.565 | 73,65 | -851.810,82 | -101,0% | |
| 2026-01-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -11.515 | 73,64 | -848.017,57 | -100,5% | |
| 2026-01-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -8.135 | 74,38 | -605.060,96 | -71,7% | |
| 2026-01-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -8.085 | 74,38 | -601.340,47 | -71,3% | |
| 2026-01-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -400 | 75,16 | -30.064,08 | -3,6% | |
| 2025-12-15 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -1.700 | 75,24 | -127.910,04 | -15,2% | |
| 2025-12-15 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -28.311 | 74,60 | -2.111.992,11 | -250,3% | |
| 2025-12-08 | Apuli Maricel | Officer, Chief Accounting Officer | Open Market Sale | -2.000 | 74,26 | -148.520,00 | -17,6% | |
| 2025-12-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.712 | 73,75 | -568.758,46 | -67,4% | |
| 2025-12-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -12.517 | 73,05 | -914.324,29 | -108,4% | |
| 2025-12-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -12.288 | 73,04 | -897.529,04 | -106,4% | |
| 2025-12-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.483 | 73,76 | -551.951,32 | -65,4% | |
| 2025-12-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -2.100 | 73,16 | -153.638,31 | -18,2% | |
| 2025-12-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -12.200 | 74,42 | -907.970,36 | -107,6% | |
| 2025-12-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -12.192 | 74,42 | -907.381,07 | -107,5% | |
| 2025-12-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.708 | 74,80 | -426.938,99 | -50,6% | |
| 2025-12-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.700 | 74,80 | -426.357,72 | -50,5% | |
| 2025-12-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -2.100 | 73,16 | -153.626,34 | -18,2% | |
| 2025-11-20 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -6.401 | 64,97 | -415.876,81 | -49,3% | |
| 2025-11-20 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -14.299 | 65,90 | -942.361,30 | -111,7% | |
| 2025-11-20 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.456 | 66,71 | -363.985,58 | -43,1% | |
| 2025-11-18 | Lo Andrew | Director | Open Market Sale | -30.993 | 66,05 | -2.047.056,66 | -242,6% | |
| 2025-11-18 | Lo Andrew | Director | Open Market Sale | -24.007 | 65,23 | -1.566.012,62 | -185,6% | |
| 2025-11-17 | Trimarchi Thomas | Officer, President and CFO | Open Market Sale | -6.956 | 66,84 | -464.937,65 | -55,1% | |
| 2025-11-17 | Lo Andrew | Director | Open Market Sale | -36.801 | 66,63 | -2.451.914,47 | -290,6% | |
| 2025-11-17 | Lo Andrew | Director | Open Market Sale | -3.798 | 67,06 | -254.678,69 | -30,2% | |
| 2025-11-17 | Scott Randal W. | Director | Open Market Sale | -6.199 | 66,89 | -414.656,07 | -49,1% | |
| 2025-11-17 | Scott Randal W. | Director | Open Market Sale | -3.801 | 66,25 | -251.809,03 | -29,8% | |
| 2025-11-17 | Trimarchi Thomas | Officer, President and CFO | Open Market Sale | -9.978 | 66,19 | -660.466,77 | -78,3% | |
| 2025-11-12 | Valantine Hannah | Director | Open Market Sale | -25.484 | 66,07 | -1.683.727,88 | -199,6% | |
| 2025-11-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -220 | 62,79 | -13.814,59 | -1,6% | |
| 2025-11-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -12.492 | 61,14 | -763.762,13 | -90,5% | |
| 2025-11-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -12.234 | 61,13 | -747.861,97 | -88,6% | |
| 2025-11-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.546 | 61,87 | -466.838,57 | -55,3% | |
| 2025-11-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.308 | 61,87 | -452.156,19 | -53,6% | |
| 2025-11-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -200 | 62,81 | -12.561,00 | -1,5% | |
| 2025-11-06 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -12.529 | 62,91 | -788.184,36 | -93,4% | |
| 2025-11-06 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -12.576 | 62,91 | -791.166,22 | -93,8% | |
| 2025-11-06 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.371 | 63,56 | -468.472,01 | -55,5% | |
| 2025-11-06 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -7.324 | 63,55 | -465.416,03 | -55,2% | |
| 2025-11-06 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -100 | 64,39 | -6.439,00 | -0,8% | |
| 2025-11-06 | DANIELS RONALD J | Director | Open Market Sale | -61.031 | 63,72 | -3.888.999,07 | -460,9% | |
| 2025-10-29 | MCCORMICK FRANK | Director | Open Market Sale | -31.116 | 66,20 | -2.059.748,51 | -244,1% | |
| 2025-10-29 | MCCORMICK FRANK | Director | Open Market Sale | -111.755 | 65,48 | -7.317.315,08 | -867,3% | |
| 2025-10-29 | MCCORMICK FRANK | Director | Open Market Sale | -43.393 | 69,24 | -3.004.349,07 | -356,1% | |
| 2025-10-29 | MCCORMICK FRANK | Director | Open Market Sale | -8.598 | 68,50 | -588.985,35 | -69,8% | |
| 2025-10-29 | MCCORMICK FRANK | Director | Open Market Sale | -3.497 | 67,52 | -236.129,68 | -28,0% | |
| 2025-10-27 | MCCORMICK FRANK | Director | Open Market Sale | -1.641 | 65,00 | -106.665,00 | -12,6% | |
| 2025-10-09 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -20.000 | 54,80 | -1.096.046,00 | -129,9% | |
| 2025-10-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -8.706 | 54,39 | -473.503,67 | -56,1% | |
| 2025-10-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -11.295 | 55,09 | -622.225,74 | -73,8% | |
| 2025-10-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -11.294 | 55,09 | -622.170,65 | -73,7% | |
| 2025-10-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -8.705 | 54,39 | -473.450,15 | -56,1% | |
| 2025-09-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -900 | 53,80 | -48.423,96 | -5,7% | |
| 2025-09-05 | MCCORMICK FRANK | Director | Open Market Sale | -74.000 | 53,16 | -3.933.544,00 | -466,2% | |
| 2025-09-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -16.900 | 53,16 | -898.449,63 | -106,5% | |
| 2025-09-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -16.800 | 53,16 | -893.124,96 | -105,9% | |
| 2025-09-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -2.300 | 51,96 | -119.513,75 | -14,2% | |
| 2025-09-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -2.300 | 51,95 | -119.495,58 | -14,2% | |
| 2025-09-05 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -800 | 53,80 | -43.039,52 | -5,1% | |
| 2025-09-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.475 | 51,85 | -283.902,29 | -33,6% | |
| 2025-09-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -14.558 | 51,16 | -744.739,24 | -88,3% | |
| 2025-09-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -14.525 | 51,15 | -742.959,56 | -88,1% | |
| 2025-09-04 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -5.442 | 51,85 | -282.186,75 | -33,4% | |
| 2025-08-21 | Trimarchi Thomas | Officer, President and CFO | Open Market Sale | -42.237 | 49,48 | -2.090.081,05 | -247,7% | |
| 2025-08-20 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -25.728 | 48,81 | -1.255.848,00 | -148,9% | |
| 2025-08-20 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -428 | 49,25 | -21.079,17 | -2,5% | |
| 2025-08-18 | Trimarchi Thomas | Officer, President and CFO | Open Market Sale | -1.973 | 50,94 | -100.512,31 | -11,9% | |
| 2025-08-18 | Trimarchi Thomas | Officer, President and CFO | Open Market Sale | -15.380 | 50,14 | -771.210,11 | -91,4% | |
| 2025-08-11 | HOMCY CHARLES J | Director | Open Market Sale | -50.000 | 48,00 | -2.400.000,00 | -284,5% | |
| 2025-08-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -11.795 | 45,88 | -541.161,68 | -64,1% | |
| 2025-08-08 | HOMCY CHARLES J | Director | Open Market Sale | -191.662 | 45,87 | -8.791.593,44 | -1042,0% | |
| 2025-08-08 | HOMCY CHARLES J | Director | Open Market Sale | -58.338 | 46,64 | -2.720.849,32 | -322,5% | |
| 2025-08-08 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -8.205 | 46,71 | -383.252,27 | -45,4% | |
| 2025-08-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -6.784 | 45,09 | -305.908,88 | -36,3% | |
| 2025-08-07 | Apuli Maricel | Officer, Chief Accounting Officer | Open Market Sale | -1.000 | 45,44 | -45.440,00 | -5,4% | |
| 2025-08-07 | Kumar Neil | Director, Officer, Chief Executive Officer | Open Market Sale | -13.216 | 45,64 | -603.151,81 | -71,5% | |
| 2025-08-05 | Ellis Andrea | Director | Open Market Sale | -17.167 | 49,00 | -841.183,00 | -99,7% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1018 von typischerweise 8355 Fonds (12 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 14.207.757 | 0 | 14.207.757 | 1.055.068.019 | Neu | +100,0% | |
| Kohlberg Kravis Roberts & Co. L.P. | 13.260.971 | 0 | 13.260.971 | 984.759.706 | Neu | +100,0% | |
| Janus Henderson Group Ltd. | 13.179.013 | 0 | 13.179.013 | 978.607.712 | Neu | +100,0% | |
| VIKING GLOBAL INVESTORS LP | 11.842.434 | 0 | 11.842.434 | 879.419.149 | Neu | +100,0% | |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 9.365.463 | 0 | 9.365.463 | 695.479.282 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.759.495 | 0 | 7.759.495 | 576.220.099 | Neu | +100,0% | |
| UBS Group AG | 5.890.321 | 0 | 5.890.321 | 437.415.238 | Neu | +100,0% | |
| Aisling Capital Management LP | 5.089.611 | 0 | 5.089.611 | 377.954.513 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 4.918.030 | 0 | 4.918.030 | 371.928.018 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 4.935.272 | 0 | 4.935.272 | 366.493.298 | Neu | +100,0% | |
| STATE STREET CORP | 4.934.320 | 0 | 4.934.320 | 366.422.603 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 3.607.243 | 0 | 3.607.243 | 267.873.865 | Neu | +100,0% | |
| Frazier Life Sciences Management, L.P. | 3.448.139 | 0 | 3.448.139 | 256.058.802 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 3.390.240 | 0 | 3.390.240 | 251.759.223 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 3.120.631 | 0 | 3.120.631 | 231.738.058 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 2.545.486 | 0 | 2.545.486 | 189.027.791 | Neu | +100,0% | |
| Polar Capital Holdings Plc | 2.519.306 | 0 | 2.519.306 | 187.083.664 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 2.483.953 | 0 | 2.483.953 | 184.458.350 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 2.438.925 | 0 | 2.438.925 | 181.114.553 | Neu | +100,0% | |
| FMR LLC | 2.343.754 | 0 | 2.343.754 | 174.047.182 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 1.977.080 | 0 | 1.977.080 | 146.817.961 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.976.094 | 0 | 1.976.094 | 146.744.740 | Neu | +100,0% | |
| ALLIANCEBERNSTEIN L.P. | 1.908.907 | 0 | 1.908.907 | 146.012.296 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 1.957.716 | 0 | 1.957.716 | 145.379.990 | Neu | +100,0% | |
| MORGAN STANLEY | 1.877.359 | 0 | 1.877.359 | 139.412.745 | Neu | +100,0% | |
| SC US (TTGP), LTD. | 1.860.364 | 0 | 1.860.364 | 138.150.631 | Neu | +100,0% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.534.736 | 0 | 1.534.736 | 113.969.000 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 1.403.642 | 0 | 1.403.642 | 104.234.454 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 1.381.184 | 0 | 1.381.184 | 101.494.628 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 1.330.415 | 0 | 1.330.415 | 98.796.618 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 1.307.176 | 0 | 1.307.176 | 97.070.890 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 1.285.748 | 0 | 1.285.748 | 95.479.673 | Neu | +100,0% | |
| Hood River Capital Management LLC | 1.265.080 | 0 | 1.265.080 | 93.944.841 | Neu | +100,0% | |
| Laurion Capital Management LP | 1.262.651 | 0 | 1.262.651 | 93.764.463 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 1.248.521 | 0 | 1.248.521 | 92.715.351 | Neu | +100,0% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.146.671 | 0 | 1.146.671 | 85.151.788 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 1.090.326 | 0 | 1.090.326 | 80.967.742 | Neu | +100,0% | |
| CITIGROUP INC | 972.483 | 0 | 972.483 | 72.216.587 | Neu | +100,0% | |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 957.989 | 0 | 957.989 | 71.140.263 | Neu | +100,0% | |
| Clearbridge Investments, LLC | 951.200 | 0 | 951.200 | 70.636.125 | Neu | +100,0% | |
| Allspring Global Investments Holdings, LLC | 889.356 | 0 | 889.356 | 66.212.554 | Neu | +100,0% | |
| Cormorant Asset Management, LP | 850.000 | 0 | 850.000 | 63.121.000 | Neu | +100,0% | |
| Deep Track Capital, LP | 841.445 | 0 | 841.445 | 62.485.706 | Neu | +100,0% | |
| Ensign Peak Advisors, Inc | 836.552 | 0 | 836.552 | 62.122.352 | Neu | +100,0% | |
| Capital Research Global Investors | 763.702 | 0 | 763.702 | 56.712.511 | Neu | +100,0% | |
| PANAGORA ASSET MANAGEMENT INC | 742.117 | 0 | 742.117 | 55.109.608 | Neu | +100,0% | |
| First Turn Management, LLC | 695.718 | 0 | 695.718 | 51.664.019 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 633.283 | 0 | 633.283 | 47.027.596 | Neu | +100,0% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 599.000 | 0 | 599.000 | 44.481.740 | Neu | +100,0% | |
| FEDERATED HERMES, INC. | 588.434 | 0 | 588.434 | 43.697.109 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1018 von typischerweise 8355 Fonds (12 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Portman Square Capital LLP | 193.600 | 193.600 | 0,0% | 14.419.328 | 41,54 | 100 % | 12 Q |
| Y-Intercept (Hong Kong) Ltd | 107.419 | 0 | +100,0% | 8.000.567 | 23,05 | 100 % | 9 Q |
| TEMA ETFS LLC | 76.076 | 112.273 | -32,2% | 5.666.140 | 16,32 | 100 % | 7 Q |
| Assenagon Asset Management S.A. | 15.620 | 44.092 | -64,6% | 1.163.378 | 3,35 | 100 % | 17 Q |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 13.202 | 4.952 | +166,6% | 1.133.939 | 3,27 | 1 % | 4 Q |
| QRG CAPITAL MANAGEMENT, INC. | 9.808 | 7.174 | +36,7% | 730.391 | 2,10 | 100 % | 3 Q |
| First Bank & Trust | 8.797 | 8.655 | +1,6% | 655.201 | 1,89 | 100 % | 9 Q |
| Perpetual Ltd | 8.583 | 0 | +100,0% | 639.262 | 1,84 | 100 % | 1 Q |
| Central Pacific Bank - Trust Division | 7.767 | 7.767 | 0,0% | 578.486 | 1,67 | 0 % | 3 Q |
| LVW Advisors, LLC | 4.333 | 4.787 | -9,5% | 322.722 | 0,93 | 0 % | 5 Q |
| DAVENPORT & Co LLC | 3.806 | 3.300 | +15,3% | 283.471 | 0,82 | 0 % | 7 Q |
| MOODY ALDRICH PARTNERS LLC | 3.455 | 75.948 | -95,5% | 257.328 | 0,74 | 100 % | 14 Q |
| Westmount Partners, LLC | 3.118 | 3.193 | -2,3% | 232.229 | 0,67 | 100 % | 3 Q |
| PSP Research LLC | 3.000 | 6.000 | -50,0% | 223.440 | 0,64 | 0 % | 3 Q |
| HARBOR INVESTMENT ADVISORY, LLC | 1.835 | 0 | +100,0% | 136.671 | 0,39 | 100 % | 1 Q |
| GAMMA Investing LLC | 1.646 | 1.447 | +13,8% | 122.594 | 0,35 | 100 % | 11 Q |
| CoreCap Advisors, LLC | 1.000 | 1.000 | 0,0% | 74.480 | 0,21 | 0 % | 5 Q |
| CONTRAVISORY INVESTMENT MANAGEMENT, INC. | 288 | 288 | 0,0% | 21.450 | 0,06 | 100 % | 4 Q |
| Cedar Mountain Advisors, LLC | 149 | 149 | 0,0% | 11.098 | 0,03 | 0 % | 2 Q |
| JFS WEALTH ADVISORS, LLC | 136 | 126 | +7,9% | 10.130 | 0,03 | 0 % | 17 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 33 | 0,3 | 20 |
| 31.03.2026 | ✓ | 453 | 215,7 | 15.484 |
| 31.12.2025 | ✓ | 424 | 196,5 | 14.315 |
| 30.09.2025 | ✓ | 388 | 196,1 | 10.981 |
| 30.06.2025 | ✓ | 352 | 191,0 | 8.038 |
| 31.03.2025 | ✓ | 296 | 193,3 | 6.572 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 9.365.463 | 695.479.282 |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.759.495 | 576.220.099 |
| Catalio Capital Management, LP | 432.014 | 32.081.360 |
| RENAISSANCE TECHNOLOGIES LLC | 365.772 | 27.162.229 |
| Fiera Capital Corp | 322.690 | 23.962.960 |
| Integral Health Asset Management, LLC | 275.000 | 20.421.500 |
| SEB Asset Management AB | 235.813 | 17.511.451 |
| Ikarian Capital, LLC | 160.120 | 11.890.511 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 63.180 | 4.691.747 |
| FIFTH THIRD BANCORP | 49.729 | 3.692.863 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | 3.173.940 | 2.475.758 | +354.6 % | 235.696.785 |
| Janus Henderson Group Ltd. | 13.179.013 | 2.178.556 | +19.8 % | 978.607.712 |
| JANE STREET GROUP, LLC | 1.757.672 | 1.415.877 | +414.2 % | 130.524.722 |
| Polar Capital Holdings Plc | 2.519.306 | 1.219.960 | +93.9 % | 187.083.664 |
| TWO SIGMA INVESTMENTS, LP | 3.120.631 | 1.173.584 | +60.3 % | 231.738.058 |
| MILLENNIUM MANAGEMENT LLC | 633.283 | 596.698 | +1631.0 % | 47.027.596 |
| GEODE CAPITAL MANAGEMENT, LLC | 4.918.030 | 505.507 | +11.5 % | 371.928.018 |
| MORGAN STANLEY | 1.877.359 | 477.550 | +34.1 % | 139.412.745 |
| JPMORGAN CHASE & CO | 1.312.259 | 453.291 | +52.8 % | 91.018.346 |
| Clearbridge Investments, LLC | 951.200 | 452.871 | +90.9 % | 70.636.125 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 11.842.434 | -2.551.500 | -17.7 % | 879.419.149 |
| Capital Research Global Investors | 763.702 | -1.170.996 | -60.5 % | 56.712.511 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.146.671 | -534.301 | -31.8 % | 85.151.788 |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 352.831 | -460.963 | -56.6 % | 26.201.230 |
| Ensign Peak Advisors, Inc | 836.552 | -426.932 | -33.8 % | 62.122.352 |
| Cormorant Asset Management, LP | 850.000 | -350.000 | -29.2 % | 63.121.000 |
| BlackRock, Inc. | 14.207.757 | -341.772 | -2.3 % | 1.055.068.019 |
| Sofinnova Investments, Inc. | 409.183 | -311.265 | -43.2 % | 30.385.930 |
| BNP PARIBAS FINANCIAL MARKETS | 1.307.176 | -285.484 | -17.9 % | 97.070.890 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 426.583 | -212.300 | -33.2 % | 31.678.054 |
Zusätzlich aktuell von 244 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck | Δ-Balken |
|---|---|---|---|---|---|---|---|
| 11.07.2026 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+6) | Aktivist (13D/A) | 5,00 % | 9.792.219 | -1,10 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The response … | |
| 29.05.2026 | Roberts, Jr., Thomas G. (+14) | Passiv (13G) | 5,20 % | 10.226.063 | Neu | – | |
| 29.05.2026 | Farallon Capital F5 Master I, L.P. (+1) | Passiv (13G) | 0,10 % | 202.722 | Neu | – | |
| 29.05.2026 | Farallon Healthcare Partners (GP), L.L.C. (+1) | Passiv (13G) | 3,00 % | 5.918.914 | Neu | – | |
| 29.05.2026 | Four Crossings Institutional Partners V, L.P. (+1) | Passiv (13G) | 0,10 % | 171.156 | Neu | – | |
| 29.05.2026 | Farallon Capital Institutional Partners, L.P. | Passiv (13G) | 0,50 % | 922.612 | Neu | – | |
| 29.05.2026 | Farallon Partners, L.L.C. | Passiv (13G) | 5,10 % | 10.023.341 | Neu | – | |
| 29.05.2026 | Farallon Capital Partners, L.P. | Passiv (13G) | 0,40 % | 728.238 | Neu | – | |
| 29.05.2026 | Farallon Capital Offshore Investors II, L.P. | Passiv (13G) | 1,00 % | 1.869.577 | Neu | – | |
| 29.05.2026 | Farallon Capital Institutional Partners III, L.P. | Passiv (13G) | 0,10 % | 145.089 | Neu | – | |
| 29.05.2026 | Farallon Capital (AM) Investors, L.P. | Passiv (13G) | 0,10 % | 100.702 | Neu | – | |
| 29.05.2026 | Farallon Capital Institutional Partners II, L.P. | Passiv (13G) | 0,10 % | 167.053 | Neu | – | |
| 15.05.2026 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 6,80 % | 13.179.013 | +1,10 pp | – | |
| 16.04.2026 | NEIL KUMAR | Passiv (13G/A) | 4,60 % | 9.282.982 | -0,81 pp | – | |
| 03.04.2026 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+6) | Aktivist (13D/A) | 6,10 % | 11.842.434 | -0,70 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -8,68 pp | – | |
| 17.02.2026 | JANUS HENDERSON GROUP PLC | Passiv (13G) | 5,70 % | 11.000.457 | Neu | – | |
| 17.02.2026 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+7) | Aktivist (13D/A) | 6,80 % | 13.026.367 | -1,40 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The response … | |
| 14.11.2025 | Viking Global Opportunities Liquid Portfolio Sub-Master LP (+5) | Aktivist (13D/A) | Ausstieg | 0 | -0,02 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 14.11.2025 | Viking Global Opportunities Illiquid Investments Sub-Master LP (+7) | Aktivist (13D/A) | 8,20 % | 15.893.934 | -0,90 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 14.11.2025 | T. Rowe Price Associates, Inc. | Passiv (13G) | 1,10 % | 885.042 | Neu | – | |
| 14.08.2025 | Viking Global Opportunities Liquid Portfolio Sub-Master LP | Aktivist (13D/A) | 0,02 % | 32.802 | -0,01 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 14.08.2025 | Viking Global Opportunities Portfolio GP LLC (+2) | Aktivist (13D/A) | 9,10 % | 17.489.651 | -0,50 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 14.08.2025 | Viking Long Fund Master Ltd. (+1) | Aktivist (13D/A) | 0,04 % | 77.532 | -0,06 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 14.08.2025 | VIKING GLOBAL PERFORMANCE LLC | Aktivist (13D/A) | 0,10 % | 213.000 | -0,10 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 14.08.2025 | Viking Global Equities Master Ltd. | Aktivist (13D/A) | 0,10 % | 208.740 | -0,10 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 14.08.2025 | HALVORSEN OLE ANDREAS (+2) | Aktivist (13D/A) | 9,70 % | 18.602.920 | Neu | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 14.08.2025 | Viking Global Equities II LP | Aktivist (13D/A) | 0,00 % | 4.260 | 0,00 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 14.08.2025 | VIKING GLOBAL INVESTORS LP | Aktivist (13D/A) | 9,30 % | 17.780.183 | -0,50 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 14.08.2025 | Viking Global Opportunities Illiquid Investments Sub-Master LP | Aktivist (13D/A) | 9,10 % | 17.456.849 | -0,40 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 29.07.2025 | The Vanguard Group | Passiv (13G/A) | 8,68 % | 16.484.985 | +1,32 pp | – | |
| 01.07.2025 | VIKING GLOBAL INVESTORS LP (+3) | Aktivist (13D/A) | 9,80 % | 18.602.920 | -1,90 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 01.07.2025 | Viking Global Opportunities Portfolio GP LLC (+2) | Aktivist (13D/A) | 9,60 % | 18.145.011 | Neu | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 01.07.2025 | Viking Long Fund Master Ltd. (+1) | Aktivist (13D/A) | 0,10 % | 118.214 | 0,00 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 01.07.2025 | Viking Global Equities Master Ltd. | Aktivist (13D/A) | 0,20 % | 332.901 | -0,10 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 01.07.2025 | Viking Global Equities II LP | Aktivist (13D/A) | 0,00 % | 6.794 | Neu | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 01.07.2025 | Viking Global Opportunities Illiquid Investments Sub-Master LP | Aktivist (13D/A) | 9,50 % | 18.089.980 | -1,80 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 01.07.2025 | Viking Global Opportunities Liquid Portfolio Sub-Master LP | Aktivist (13D/A) | 0,03 % | 55.031 | Neu | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 01.07.2025 | VIKING GLOBAL PERFORMANCE LLC | Aktivist (13D/A) | 0,20 % | 339.695 | Neu | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The respons… | |
| 14.05.2025 | KKR Genetic Disorder GP LLC (+8) | Aktivist (13D/A) | 7,00 % | 13.260.971 | -3,10 pp | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The informa… |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 11.05.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 29.04.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 19.03.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 18.03.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 03.03.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 22.09.2025 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 08.08.2025 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 194.515.000 $ | – | -0,84 $ | 1.370.981.000 $ | -2.278.363.000 $ |
| 2025-12-31 | 10-K | 502.076.000 $ | – | -3,78 $ | 936.025.000 $ | -2.086.610.000 $ |
| 2025-09-30 | 10-Q | 120.700.000 $ | – | -0,95 $ | 998.250.000 $ | -1.933.070.000 $ |
| 2025-06-30 | 10-Q | 110.565.000 $ | – | -0,95 $ | 1.080.190.000 $ | -1.787.860.000 $ |
| 2025-03-31 | 10-Q | 116.633.000 $ | – | -0,88 $ | 881.638.000 $ | -1.648.395.000 $ |
| 2024-12-31 | 10-K | 221.902.000 $ | – | -2,88 $ | 919.338.000 $ | -1.467.904.000 $ |
| 2024-09-30 | 10-Q | 2.732.000 $ | – | -0,86 $ | 664.977.000 $ | -1.229.922.000 $ |
| 2024-06-30 | 10-Q | 2.168.000 $ | – | -0,39 $ | 794.375.000 $ | -1.092.925.000 $ |
| 2024-03-31 | 10-Q | 211.120.000 $ | – | -0,20 $ | 849.333.000 $ | -1.049.528.000 $ |
| 2023-12-31 | 10-K | 9.303.000 $ | – | -3,95 $ | 546.380.000 $ | -1.354.257.000 $ |
| 2023-09-30 | 10-Q | 4.091.000 $ | – | -1,08 $ | 655.008.000 $ | -1.207.543.000 $ |
| 2023-06-30 | 10-Q | 1.641.000 $ | – | -0,98 $ | 503.661.000 $ | -1.362.023.000 $ |
| 2023-03-31 | 10-Q | 1.826.000 $ | – | -0,92 $ | 625.680.000 $ | -1.225.665.000 $ |
| 2022-12-31 | 10-K | 77.648.000 $ | – | -3,26 $ | 623.036.000 $ | -1.254.617.000 $ |
| 2022-09-30 | 10-Q | 338.000 $ | – | -0,93 $ | 728.740.000 $ | -1.138.417.000 $ |
| 2022-06-30 | 10-Q | 73.746.000 $ | – | -0,07 $ | 862.233.000 $ | -1.025.532.000 $ |
| 2022-03-31 | 10-Q | 1.694.000 $ | – | -1,35 $ | 813.149.000 $ | -1.040.996.000 $ |
| 2021-12-31 | 10-K | 69.716.000 $ | – | -3,90 $ | 1.012.792.000 $ | -870.414.000 $ |
| 2021-09-30 | 10-Q | 2.344.000 $ | – | -1,06 $ | 781.524.000 $ | -743.397.000 $ |
| 2021-06-30 | 10-Q | 54.024.000 $ | – | -0,66 $ | 1.081.486.000 $ | -464.294.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 362,4 Mio. | – | – | – | 3,8 Mio. | 72,2 % | Neu | |
| License And Service | 128,3 Mio. | – | – | – | – | 25,6 % | Neu | |
| Royalty | 11,4 Mio. | – | – | – | – | 2,3 % | Neu | |
| Reportable Segment Aggregation Before Other Operating Segment | – | 221,9 Mio. | 9,3 Mio. | 77,6 Mio. | – | – | – | |
| License | – | – | – | – | 65,9 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 07.05.2026 | 194,5 Mio. USD | -0,84 |
| Q3 2025 | 30.09.2025 | 29.10.2025 | 120,7 Mio. USD | -0,95 |
| Q2 2025 | 30.06.2025 | 05.08.2025 | 110,6 Mio. USD | -0,95 |
| Q1 2025 | 31.03.2025 | 29.04.2025 | 116,6 Mio. USD | -0,88 |
| Q3 2024 | 30.09.2024 | 12.11.2024 | 2,7 Mio. USD | -0,86 |
| Q2 2024 | 30.06.2024 | 01.08.2024 | 2,2 Mio. USD | -0,39 |
| Q1 2024 | 31.03.2024 | 02.05.2024 | 211,1 Mio. USD | -0,20 |
| Q3 2023 | 30.09.2023 | 02.11.2023 | 4,1 Mio. USD | -1,08 |
| Q2 2023 | 30.06.2023 | 03.08.2023 | 1,6 Mio. USD | -0,98 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 07.05.2026 | 10-Q | 31.03.2026 | 37 Tage | SEC » |
| 24.02.2026 | 10-K | 31.12.2025 | 55 Tage | SEC » |
| 29.10.2025 | 10-Q | 30.09.2025 | 29 Tage | SEC » |
| 05.08.2025 | 10-Q | 30.06.2025 | 36 Tage | SEC » |
| 29.04.2025 | 10-Q | 31.03.2025 | 29 Tage | SEC » |
| 20.02.2025 | 10-K | 31.12.2024 | 51 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 01.08.2024 | 10-Q | 30.06.2024 | 32 Tage | SEC » |
| 02.05.2024 | 10-Q | 31.03.2024 | 32 Tage | SEC » |
| 22.02.2024 | 10-K | 31.12.2023 | 53 Tage | SEC » |
| 02.11.2023 | 10-Q | 30.09.2023 | 33 Tage | SEC » |
| 03.08.2023 | 10-Q | 30.06.2023 | 34 Tage | SEC » |
| 04.05.2023 | 10-Q | 31.03.2023 | 34 Tage | SEC » |
| 23.02.2023 | 10-K | 31.12.2022 | 54 Tage | SEC » |
| 03.11.2022 | 10-Q | 30.09.2022 | 34 Tage | SEC » |
| 04.08.2022 | 10-Q | 30.06.2022 | 35 Tage | SEC » |
| 05.05.2022 | 10-Q | 31.03.2022 | 35 Tage | SEC » |
| 25.02.2022 | 10-K | 31.12.2021 | 56 Tage | SEC » |
| 04.11.2021 | 10-Q | 30.09.2021 | 35 Tage | SEC » |
| 05.08.2021 | 10-Q | 30.06.2021 | 36 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 25.02.2021 | 10-K | 31.12.2020 | 56 Tage | SEC » |
| 05.11.2020 | 10-Q | 30.09.2020 | 36 Tage | SEC » |
| 11.08.2020 | 10-Q | 30.06.2020 | 42 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 06.03.2024 | Kapitalerhöhung | – | SEC » |
| 04.03.2024 | Kapitalerhöhung | – | SEC » |
| 09.03.2023 | Kapitalerhöhung | – | SEC » |
| 06.03.2023 | Kapitalerhöhung | – | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | Form | |
|---|---|---|---|
| 24.04.2026 | HV-Einladung | DEFA14A | SEC » |
| 24.04.2026 | HV-Einladung | DEF 14A | SEC » |
| 09.05.2025 | HV-Einladung | DEFA14A | SEC » |
| 30.04.2025 | HV-Einladung | DEFA14A | SEC » |
| 30.04.2025 | HV-Einladung | DEF 14A | SEC » |
| 16.04.2025 | Vorläufig | PRE 14A | SEC » |
| 25.04.2024 | HV-Einladung | DEFA14A | SEC » |
| 25.04.2024 | HV-Einladung | DEF 14A | SEC » |
| 28.04.2023 | HV-Einladung | DEFA14A | SEC » |
| 28.04.2023 | HV-Einladung | DEF 14A | SEC » |
| 29.04.2022 | HV-Einladung | DEFA14A | SEC » |
| 29.04.2022 | HV-Einladung | DEF 14A | SEC » |
| 08.11.2021 | HV-Einladung | DEF 14A | SEC » |
| 29.10.2021 | Vorläufig | PRE 14A | SEC » |
| 30.04.2021 | HV-Einladung | DEF 14A | SEC » |
| 15.12.2020 | M&A-Abstimmung | DEFM14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termine und Vergütung stehen im Dokument (SEC-Link).
Übernahmen & Fusionen (M&A)
M&A-relevante SEC-Filings der letzten sechs Jahre: Übernahmeangebote (Tender Offers), Fusionen (425/S-4), Aktienrückkauf-Angebote (Self-Tender) und Going-Private-Transaktionen. Geführt nach dem einreichenden Emittenten.
| Datum (US) | Kategorie | Form | Deal-Konditionen | SEC |
|---|---|---|---|---|
| 11.12.2020 | Fusion | S-4/A | Ziel: Eidos Therapeutics, Inc. · $73,26 Cash + Aktien | SEC » |
| 06.11.2020 | Fusion | S-4 | Ziel: Eidos Therapeutics, Inc. · Umtausch 1,85 Akt./Ziel-Aktie | SEC » |
| 06.10.2020 | Fusion | 425 | Ziel: BRIDGEBIO PHARMA, INC. | SEC » |
| 05.10.2020 | Fusion | 425 | Ziel: Eidos Therapeutics, Inc. · $73,26 Cash + Aktien | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Deal-Konditionen aus dem Dokument extrahiert (Tender: SC TO-T/-I/SC 14D9; Fusion: 425/S-4 — Gegenpartei + Umtauschverhältnis), ohne Gewähr — Original siehe SEC-Link.
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (26.06.2026)
HOCH Abgang Schlüsselpersonen (26.06.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 02.07.2026 | Volltext-Klassifikation | InsolvenzDelisting-Risiko | EXTREM | SEC | petition for bankruptcy · notice of delisting |
| 26.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 17.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 02.07.2026 | Finanzierung/Anleihe | 0,00 | 65 | BridgeBio Pharma hat am 1. Juli 2026 eine Preferred Stock Placement mit Chinotto Investments abgeschlossen. Die Aktien sind konvertierbar in… 🔒 | SEC |
| 26.06.2026 | Personalwechsel | 0,00 | 28 | Dr. Randal W. Scott verließ den Vorstand nach Ablauf seines Class-I-Mandats am 22. Juni 2026. Die Jahresversammlung stimmte routinemäßig übe… 🔒 | SEC |
| 27.05.2026 | Behördliche Maßnahme | 0,65 | 78 | BridgeBio Pharma gibt bekannt, dass die FDA die NDA für BBP-418 zur Behandlung von LGMD2I/R9 akzeptiert hat und Priority Review gewährt. | SEC |
| 13.05.2026 | Behördliche Maßnahme | 0,45 | 50 | BridgeBio reicht NDA bei der FDA für Encaleret zur Behandlung von ADH1 ein, ein wichtiger Meilenstein der Arzneimittelentwicklung. | SEC |
| 08.05.2026 | Wesentliche Vereinbarung | -0,10 | 65 | BridgeBio Pharma hat ein neues Eigenkapital-Distributionsabkommen mit Goldman Sachs abgeschlossen und beendet das vorherige Abkommen von Mai… 🔒 | SEC |
| 07.05.2026 | Quartalszahlen | 0,30 | 60 | BridgeBio Pharma meldete Q1 2026-Ergebnisse und genehmigte ein $500-Mio. Aktienrückkaufprogramm. Das Unternehmen kann Aktien flexibel am Mar… 🔒 | SEC |
| 30.03.2026 | Sonstiges | 0,80 | 85 | BridgeBio Pharma reicht Zulassungsantrag (NDA) bei der FDA für BBP-418 zur Behandlung von LGMD2I/R9 ein. Die Einreichung markiert einen wich… 🔒 | SEC |
| 24.02.2026 | Quartalszahlen | 0,00 | 45 | BridgeBio Pharma berichtet Geschäftsergebnisse und Geschäftsupdates für Q4 und Gesamtjahr 2025. Der Volltext der Pressemitteilung befindet s… 🔒 | SEC |
| 12.02.2026 | Sonstiges | 0,75 | 72 | BridgeBio berichtet positive Phase-3-Topline-Ergebnisse für das orale Infigratinib mit statistisch signifikanten Verbesserungen der Körperpr… 🔒 | SEC |
| 21.01.2026 | Finanzierung/Anleihe | 0,40 | 75 | BridgeBio Pharma gab 632,5 Millionen US-Dollar an 0,75%-Wandelanleihen (fällig 2033) aus. Die Emission wurde unter Nutzung von SEC-Ausnahmen… 🔒 | SEC |
| 12.01.2026 | Quartalszahlen | 0,10 | 45 | BridgeBio präsentierte ungeprüfte vorläufige Jahresergebnisse 2025 sowie ein Business Update bei der 44. J.P. Morgan Healthcare Conference; … 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 1.697.839 | 72,01 | 122.261.386 |
| 2026-06-29 | 1.647.278 | 70,24 | 115.704.807 |
| 2026-06-26 | 93 | 69,69 | 6.481 |
| 2026-06-25 | 522 | 69,36 | 36.206 |
| 2026-06-15 | 187 | 66,80 | 12.492 |
| 2026-06-05 | 7 | 67,33 | 471 |
| 2026-06-02 | 28.830 | 65,36 | 1.884.329 |
| 2026-05-29 | 390 | 68,45 | 26.696 |
| 2026-05-19 | 68 | 65,32 | 4.442 |
| 2026-05-13 | 8 | 65,95 | 528 |
| 2026-05-11 | 13 | 67,39 | 876 |
| 2026-05-08 | 3.016 | 67,45 | 203.429 |
| 2026-05-05 | 20.622 | 68,99 | 1.422.712 |
| 2026-05-04 | 18.993 | 68,56 | 1.302.160 |
| 2026-04-30 | 22.615 | 70,94 | 1.604.308 |
| 2026-04-29 | 117 | 69,71 | 8.156 |
| 2026-04-27 | 56 | 73,28 | 4.104 |
| 2026-04-21 | 2.292 | 76,68 | 175.751 |
| 2026-04-20 | 868 | 76,75 | 66.619 |
| 2026-04-15 | 1 | 77,93 | 78 |
| 2026-04-09 | 100 | 74,14 | 7.414 |
| 2026-04-02 | 699 | 74,45 | 52.041 |
| 2026-03-30 | 8 | 69,70 | 558 |
| 2026-03-24 | 2.684 | 69,60 | 186.806 |
| 2026-03-20 | 5.894 | 70,07 | 412.993 |
| 2026-03-19 | 65.560 | 70,12 | 4.597.067 |
| 2026-03-18 | 1 | 70,94 | 71 |
| 2026-03-11 | 284 | 74,32 | 21.107 |
| 2026-03-10 | 179 | 65,64 | 11.750 |
| 2026-03-05 | 8.471 | 66,54 | 563.660 |
| 2026-03-04 | 125 | 64,53 | 8.066 |
| 2026-03-03 | 128 | 65,50 | 8.384 |
| 2026-03-02 | 915 | 66,48 | 60.829 |
| 2026-02-27 | 1.188 | 67,61 | 80.321 |
| 2026-02-26 | 705 | 66,54 | 46.911 |
| 2026-02-24 | 714 | 67,91 | 48.488 |
| 2026-02-09 | 438 | 68,05 | 29.806 |
| 2026-02-04 | 10.257 | 78,18 | 801.892 |
| 2026-02-03 | 1 | 78,24 | 78 |
| 2026-01-23 | 19.228 | 79,91 | 1.536.509 |
| 2026-01-20 | 89.717 | 76,26 | 6.841.818 |